Neos Therapeutics, Inc. 4
4 · Neos Therapeutics, Inc. · Filed Jul 28, 2015
Insider Transaction Report
Form 4
Engelking Dorothy
VP, Regulatory Affairs
Transactions
- Conversion
Series C Preferred Stock
2015-07-28−1,000→ 0 total→ Common Stock (416 underlying) - Conversion
Common Stock
2015-07-28+416→ 416 total
Footnotes (1)
- [F1]Each share of the Issuer's Series C preferred stock was automatically converted on a 2.4-for-1 basis into common stock immediately prior to the closing of the Issuer's initial public offering. The shares of Series C preferred stock had no expiration date.